Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI

Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results from the Phase 3 BASIS study evaluating HYMPAVZI for adults and adolescents living with hemophilia A or B with inhibitors. Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock The results showed the superiority of HYMPAVZI for the improvement of bleeding outcomes in comparison with on-demand (OD) treatment with bypassing agents, reducing bleeds by 93% in ado ...